DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer
Ovarian carcinoma (OV) is a lethal gynecological malignancy. Most OV patients develop resistance to platinum-based chemotherapy and recurrence. Peroxisome proliferator-activated receptors (PPARs) are the ligand activating transcription factor of the nuclear receptor superfamily. PPARs as important t...
Saved in:
Main Authors: | Qianqian Zhao, Jie Zhong, Ping Lu, Xiao Feng, Ying Han, Chenqi Ling, Wenke Guo, Weijin Zhou, Fudong Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2021/6629842 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
by: Wang Caixia, et al.
Published: (2025-01-01) -
CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer
by: Pan Hu, et al.
Published: (2023-01-01) -
Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01) -
Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer
by: Woraporn Sinsuwan, et al.
Published: (2023-01-01) -
Role of PPARG in Chemosensitivity-Regulating Network for Hypopharyngeal Squamous Cell Carcinoma
by: Fanyong Kong, et al.
Published: (2023-01-01)